195 related articles for article (PubMed ID: 36087745)
1. Public health perspective of a pentavalent meningococcal vaccine combining antigens of MenACWY-CRM and 4CMenB.
Bekkat-Berkani R; Fragapane E; Preiss S; Rappuoli R; Sohn WY; Soumahoro L; Vadivelu K
J Infect; 2022 Nov; 85(5):481-491. PubMed ID: 36087745
[TBL] [Abstract][Full Text] [Related]
2. Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile.
Graña MG; Cavada G; Vasquez M; Shen J; Maervoet J; Klint J; Gómez JA
Hum Vaccin Immunother; 2021 Dec; 17(12):5603-5613. PubMed ID: 34890520
[TBL] [Abstract][Full Text] [Related]
3. Potential public health impact of a
Huang L; Snedecor SJ; Balmer P; Srivastava A
Postgrad Med; 2022 May; 134(4):341-348. PubMed ID: 33615973
[TBL] [Abstract][Full Text] [Related]
4. A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial.
Block SL; Szenborn L; Daly W; Jackowska T; D'Agostino D; Han L; Dull PM; Smolenov I
Vaccine; 2015 May; 33(21):2500-10. PubMed ID: 25795256
[TBL] [Abstract][Full Text] [Related]
5. A Decade of Fighting Invasive Meningococcal Disease: A Narrative Review of Clinical and Real-World Experience with the MenACWY-CRM Conjugate Vaccine.
Ruiz Garcia Y; Abitbol V; Pellegrini M; Bekkat-Berkani R; Soumahoro L
Infect Dis Ther; 2022 Apr; 11(2):639-655. PubMed ID: 34591258
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and Safety of Investigational MenABCWY Vaccine and of 4CMenB and MenACWY Vaccines Administered Concomitantly or Alone: a Phase 2 Randomized Study of Adolescents and Young Adults.
Beran J; Dražan D; Enweonye I; Bhusal C; Toneatto D
mSphere; 2021 Dec; 6(6):e0055321. PubMed ID: 34787449
[TBL] [Abstract][Full Text] [Related]
7. Modelling the impact of 4CMenB and MenACWY meningococcal combined vaccination strategies including potential 4CMenB cross-protection: An application to England.
Beck E; Klint J; Garcia S; Abbing V; Abitbol V; Akerborg O; Argante L; Bekkat-Berkani R; Hogea C; Neine M; Vadivelu K; Whelan J; Meszaros K
Vaccine; 2020 Nov; 38(47):7558-7568. PubMed ID: 32807531
[TBL] [Abstract][Full Text] [Related]
8. Immune Responses to Booster Vaccination With Meningococcal ABCWY Vaccine After Primary Vaccination With Either Investigational or Licensed Vaccines: A Phase 2 Randomized Study.
Szenborn L; Block SL; Jackowska T; Konior R; D'Agostino D; Smolenov I; Toneatto D; Welsch JA
Pediatr Infect Dis J; 2018 May; 37(5):475-482. PubMed ID: 29329168
[TBL] [Abstract][Full Text] [Related]
9. 'Be on the TEAM' Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents.
Carr J; Plested E; Aley P; Camara S; Davis K; MacLennan JM; Gray S; Faust SN; Borrow R; Christensen H; Trotter C; Maiden MCJ; Finn A; Snape MD;
BMJ Open; 2020 Oct; 10(10):e037358. PubMed ID: 33093030
[TBL] [Abstract][Full Text] [Related]
10. Breadth of coverage against a panel of 110 invasive disease isolates, immunogenicity and safety for 2 and 3 doses of an investigational MenABCWY vaccine in US adolescents - Results from a randomized, controlled, observer-blind phase II study.
Welsch JA; Senders S; Essink B; Klein T; Smolenov I; Pedotti P; Barbi S; Verma B; Toneatto D
Vaccine; 2018 Aug; 36(35):5309-5317. PubMed ID: 30061029
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates.
Kimura A; Toneatto D; Kleinschmidt A; Wang H; Dull P
Clin Vaccine Immunol; 2011 Mar; 18(3):483-6. PubMed ID: 21177912
[TBL] [Abstract][Full Text] [Related]
12. Use of the Pfizer Pentavalent Meningococcal Vaccine Among Persons Aged ≥10 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.
Collins JP; Crowe SJ; Ortega-Sanchez IR; Bahta L; Campos-Outcalt D; Loehr J; Morgan RL; Poehling KA; McNamara LA
MMWR Morb Mortal Wkly Rep; 2024 Apr; 73(15):345-350. PubMed ID: 38635488
[TBL] [Abstract][Full Text] [Related]
13. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial.
Read RC; Baxter D; Chadwick DR; Faust SN; Finn A; Gordon SB; Heath PT; Lewis DJ; Pollard AJ; Turner DP; Bazaz R; Ganguli A; Havelock T; Neal KR; Okike IO; Morales-Aza B; Patel K; Snape MD; Williams J; Gilchrist S; Gray SJ; Maiden MC; Toneatto D; Wang H; McCarthy M; Dull PM; Borrow R
Lancet; 2014 Dec; 384(9960):2123-31. PubMed ID: 25145775
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescents.
Saez-Llorens X; Aguilera Vaca DC; Abarca K; Maho E; Graña MG; Heijnen E; Smolenov I; Dull PM
Hum Vaccin Immunother; 2015; 11(6):1507-17. PubMed ID: 25969894
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age.
Marshall GS; Pelton SI; Robertson CA; Oster P
Hum Vaccin Immunother; 2022 Nov; 18(6):2099142. PubMed ID: 35947774
[TBL] [Abstract][Full Text] [Related]
16. Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants.
Abdelnour A; Silas PE; Lamas MR; Aragón CF; Chiu NC; Chiu CH; Acuña TH; Castrejón Tde L; Izu A; Odrljin T; Smolenov I; Hohenboken M; Dull PM
Vaccine; 2014 Feb; 32(8):965-72. PubMed ID: 24397906
[TBL] [Abstract][Full Text] [Related]
17. Meningococcal vaccine evolution.
Bona G; Guidi C
J Prev Med Hyg; 2012 Sep; 53(3):131-5. PubMed ID: 23362617
[TBL] [Abstract][Full Text] [Related]
18. Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine in Healthy Meningococcal-Naïve Children 2-9 Years of Age: A Phase III, Randomized Study.
Baccarini CI; Simon MW; Brandon D; Christensen S; Jordanov E; Dhingra MS
Pediatr Infect Dis J; 2020 Oct; 39(10):955-960. PubMed ID: 32852352
[TBL] [Abstract][Full Text] [Related]
19. Evolving strategies for meningococcal vaccination in Europe: Overview and key determinants for current and future considerations.
Martinón-Torres F; Taha MK; Knuf M; Abbing-Karahagopian V; Pellegrini M; Bekkat-Berkani R; Abitbol V
Pathog Glob Health; 2022 Mar; 116(2):85-98. PubMed ID: 34569453
[TBL] [Abstract][Full Text] [Related]
20. An update of clinical experience with the quadrivalent meningococcal ACWY-CRM conjugate vaccine.
Keshavan P; Pellegrini M; Vadivelu-Pechai K; Nissen M
Expert Rev Vaccines; 2018 Oct; 17(10):865-880. PubMed ID: 30198805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]